Prasetyanti Pramudita R, Medema Jan Paul
Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental Molecular Medicine (CEMM), Academic Medical Center (AMC), University of Amsterdam, 1105AZ, Amsterdam, The Netherlands.
Cancer Center Amsterdam and Cancer Genomics Center, Amsterdam, The Netherlands.
Mol Cancer. 2017 Feb 16;16(1):41. doi: 10.1186/s12943-017-0600-4.
Tumor heterogeneity represents an ongoing challenge in the field of cancer therapy. Heterogeneity is evident between cancers from different patients (inter-tumor heterogeneity) and within a single tumor (intra-tumor heterogeneity). The latter includes phenotypic diversity such as cell surface markers, (epi)genetic abnormality, growth rate, apoptosis and other hallmarks of cancer that eventually drive disease progression and treatment failure. Cancer stem cells (CSCs) have been put forward to be one of the determining factors that contribute to intra-tumor heterogeneity. However, recent findings have shown that the stem-like state in a given tumor cell is a plastic quality. A corollary to this view is that stemness traits can be acquired via (epi)genetic modification and/or interaction with the tumor microenvironment (TME). Here we discuss factors contributing to this CSC heterogeneity and the potential implications for cancer therapy.
肿瘤异质性是癌症治疗领域持续面临的挑战。异质性在不同患者的癌症之间(肿瘤间异质性)以及单个肿瘤内部(肿瘤内异质性)都很明显。后者包括表型多样性,如细胞表面标志物、(表观)遗传异常、生长速率、凋亡以及其他最终导致疾病进展和治疗失败的癌症特征。癌症干细胞(CSCs)已被提出是导致肿瘤内异质性的决定性因素之一。然而,最近的研究结果表明,特定肿瘤细胞中的干细胞样状态具有可塑性。这一观点的一个必然结果是,干性特征可以通过(表观)遗传修饰和/或与肿瘤微环境(TME)相互作用而获得。在这里,我们讨论促成这种癌症干细胞异质性的因素及其对癌症治疗的潜在影响。